{"id":"midazolam-active-placebo","safety":{"commonSideEffects":[{"rate":"common","effect":"Sedation"},{"rate":"common","effect":"Dizziness"},{"rate":"10-20","effect":"Headache"},{"rate":"dose-dependent","effect":"Respiratory depression"},{"rate":"common","effect":"Amnesia"},{"rate":"5-15","effect":"Hypotension"},{"rate":"rare","effect":"Paradoxical agitation"}]},"_chembl":{"chemblId":"CHEMBL655","moleculeType":"Small molecule","molecularWeight":"325.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midazolam binds to GABA-A receptors and potentiates the effect of the inhibitory neurotransmitter GABA, leading to increased chloride ion influx and neuronal hyperpolarization. This results in central nervous system depression characterized by sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. When used as an active placebo in clinical trials, midazolam at sub-therapeutic doses may produce subtle effects that help maintain trial blinding.","oneSentence":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation and anxiolysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:10.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sedation and anxiolysis in perioperative settings"},{"name":"Acute anxiety and agitation"},{"name":"Seizure management"},{"name":"Preoperative medication"}]},"trialDetails":[{"nctId":"NCT06608277","phase":"PHASE2","title":"Ketamine, SGB and Combination Treatment for TBI","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-07-02","conditions":"Posttraumatic Headache, Posttraumatic Stress Disorder","enrollment":175},{"nctId":"NCT07408193","phase":"EARLY_PHASE1","title":"The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2026-03","conditions":"Opioid-Refractory Chronic Cancer-Related Pain","enrollment":24},{"nctId":"NCT06496750","phase":"PHASE2","title":"Ketamine for Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-09-11","conditions":"Substance Use Disorders, Substance Use, Methamphetamine Abuse","enrollment":120},{"nctId":"NCT05631704","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-12-02","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT06330584","phase":"PHASE2","title":"Administration of Intranasal Midazolam for Anxiety in Palliative Care","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-12-20","conditions":"Anxiety, Acute Anxiety, Palliative Care","enrollment":36},{"nctId":"NCT05045378","phase":"PHASE4","title":"Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2022-03-15","conditions":"Treatment-resistant Depression, Major Depressive Disorder","enrollment":12},{"nctId":"NCT07021521","phase":"NA","title":"Midazolam Efficacy/Safety in Pre-Eclamptic C-Section Sedation","status":"COMPLETED","sponsor":"Zhuji People's Hospital of Zhejiang Province","startDate":"2021-04-05","conditions":"Midazolam, Pre-eclampsia, Cesarean Section","enrollment":124},{"nctId":"NCT06205381","phase":"PHASE1","title":"Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers","status":"COMPLETED","sponsor":"Aeovian Pharmaceuticals, Inc.","startDate":"2024-01-31","conditions":"Healthy Participants","enrollment":89},{"nctId":"NCT05895838","phase":"PHASE3","title":"The Danish Out-of-Hospital Cardiac Arrest Study","status":"RECRUITING","sponsor":"Christian Hassager","startDate":"2023-06-16","conditions":"Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome","enrollment":1000},{"nctId":"NCT06752759","phase":"PHASE3","title":"Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting","status":"RECRUITING","sponsor":"Theresa Jacob, PhD, MPH","startDate":"2024-10-16","conditions":"Severe Depression, Moderate Depression, Ketamine","enrollment":40},{"nctId":"NCT05945147","phase":"PHASE2","title":"Ketamine and Midazolam Infusions for CRPS: Feasibility Study","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2099-01-01","conditions":"Complex Regional Pain Syndromes","enrollment":""},{"nctId":"NCT06090422","phase":"PHASE1, PHASE2","title":"Ketamine for Combined Depression and Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"University Hospital of North Norway","startDate":"2025-01-01","conditions":"Depression, Alcohol Use Disorder","enrollment":34},{"nctId":"NCT04912115","phase":"PHASE2","title":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","status":"SUSPENDED","sponsor":"PharmaTher Inc.","startDate":"2021-10-05","conditions":"Dyskinesias, Movement Disorders, Central Nervous System Diseases","enrollment":30},{"nctId":"NCT03395314","phase":"PHASE2","title":"Ketamine in Borderline Personality Disorder","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-02-15","conditions":"Borderline Personality Disorder","enrollment":22},{"nctId":"NCT04019834","phase":"EARLY_PHASE1","title":"Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-07-06","conditions":"Breast Cancer, Mastectomy, Anesthesia, Local","enrollment":21},{"nctId":"NCT05192629","phase":"PHASE3","title":"Intranasal Dexmedetomidine Versus Oral Midazolam as Premedication for Propofol Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging","status":"UNKNOWN","sponsor":"Brugmann University Hospital","startDate":"2022-03-09","conditions":"MRI, Pediatric Sedation, Midazolam","enrollment":250},{"nctId":"NCT04027192","phase":"PHASE1","title":"Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-07-31","conditions":"Endometriosis","enrollment":50},{"nctId":"NCT02290873","phase":"PHASE3","title":"A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients","status":"COMPLETED","sponsor":"Paion UK Ltd.","startDate":"2015-03-30","conditions":"Colonoscopy","enrollment":461},{"nctId":"NCT03246724","phase":"PHASE4","title":"Oral Versus Intravenous Sedation for Ocular Procedures","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-10-16","conditions":"Surgery, Sedation","enrollment":327},{"nctId":"NCT03140527","phase":"PHASE1","title":"Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Proteostasis Therapeutics, Inc.","startDate":"2017-04-10","conditions":"Healthy Volunteer, Cystic Fibrosis","enrollment":171},{"nctId":"NCT04142762","phase":"PHASE1","title":"A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2019-10-18","conditions":"Chronic Hepatitis B","enrollment":80},{"nctId":"NCT03436121","phase":"PHASE2, PHASE3","title":"Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department","status":"WITHDRAWN","sponsor":"Maria Pacella","startDate":"2019-12","conditions":"Acute Pain, Depression","enrollment":""},{"nctId":"NCT03165097","phase":"PHASE1","title":"Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-07-07","conditions":"Healthy Subjects","enrollment":46},{"nctId":"NCT01999777","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2013-11","conditions":"Epilepsy","enrollment":62},{"nctId":"NCT03199339","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2017-08-29","conditions":"Tuberculosis, Tuberculosis, Pulmonary","enrollment":74},{"nctId":"NCT03666390","phase":"NA","title":"Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2018-09-10","conditions":"Major Depressive Disorder","enrollment":48},{"nctId":"NCT01945047","phase":"PHASE2, PHASE3","title":"Action of Ketamine in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2013-05","conditions":"Treatment-resistant Depression","enrollment":46},{"nctId":"NCT01920555","phase":"PHASE2","title":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-12","conditions":"Treatment Resistant Depression","enrollment":99},{"nctId":"NCT02593643","phase":"EARLY_PHASE1","title":"Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2016-01","conditions":"Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder","enrollment":9},{"nctId":"NCT00646646","phase":"NA","title":"The Effect of Sedation on Eye Movements","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-04","conditions":"Saccadic Eye Movements","enrollment":65},{"nctId":"NCT00928772","phase":"PHASE4","title":"Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety","status":"TERMINATED","sponsor":"University of Oklahoma","startDate":"2009-07","conditions":"Anxiety","enrollment":115},{"nctId":"NCT02985697","phase":"PHASE4","title":"Safety and Efficacy of Intranasal Dexmedetomidine","status":"UNKNOWN","sponsor":"Bon Secours Pediatric Dental Associates","startDate":"2017-01","conditions":"Safety and Efficacy of Intranasal Dexmedetomidine","enrollment":100},{"nctId":"NCT02629146","phase":"PHASE4","title":"Analgesic Effects of Midazolam in Human Volunteers","status":"COMPLETED","sponsor":"Wilhelminenspital Vienna","startDate":"2015-12","conditions":"Analgesic Drugs, Antinociceptive Agents","enrollment":24},{"nctId":"NCT02504476","phase":"PHASE1","title":"Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-08","conditions":"Schizophrenia or Schizoaffective Disorder","enrollment":52},{"nctId":"NCT00750191","phase":"PHASE1","title":"Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty","status":"COMPLETED","sponsor":"Baylis Medical Company","startDate":"2007-09","conditions":"Lower Back Pain","enrollment":64},{"nctId":"NCT01795222","phase":"PHASE4","title":"Midazolam Efficacy for Sedating Preschoolers Undergoing Dental Treatment","status":"COMPLETED","sponsor":"Universidade Federal de Goias","startDate":"2012-03","conditions":"Early Childhood Caries","enrollment":18},{"nctId":"NCT01441505","phase":"PHASE2","title":"A Study of Ketamine as an Antidepressant","status":"UNKNOWN","sponsor":"The University of New South Wales","startDate":"2011-09","conditions":"Major Depressive Episode","enrollment":42},{"nctId":"NCT01015482","phase":"PHASE4","title":"The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2009-11","conditions":"Hyperalgesia","enrollment":24},{"nctId":"NCT00811837","phase":"PHASE4","title":"The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2009-01","conditions":"Hyperalgesia","enrollment":24},{"nctId":"NCT00886106","phase":"PHASE4","title":"The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2009-06","conditions":"Hyperalgesia","enrollment":24},{"nctId":"NCT00789386","phase":"PHASE4","title":"The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-11","conditions":"Hyperalgesia","enrollment":24},{"nctId":"NCT00692510","phase":"PHASE1","title":"Drug Interaction Study Between AZD3480 and Cytochrome P450","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-11","conditions":"Metabolism, Alzheimer's Disease","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Midazolam (active placebo)","genericName":"Midazolam (active placebo)","companyName":"Taipei Veterans General Hospital, Taiwan","companyId":"taipei-veterans-general-hospital-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, producing sedation, anxiolysis, and amnesia. Used for Sedation and anxiolysis in perioperative and intensive care settings, Acute seizure management, Preoperative anxiety and sedation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}